Demographic Trends and the Open-Angle Glaucoma Market Opportunities and Challenges | Key Companies- Qlaris Bio, Aerpio Pharmaceuticals, and Others

The Open-Angle Glaucoma market report provides current treatment practices, emerging drugs, Open-Angle Glaucoma market share of the individual therapies, current and forecasted Open-Angle Glaucoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Open-Angle Glaucoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Open-Angle Glaucoma market.

Key Takeaways from the Open-Angle Glaucoma Market Research Report

• According to DelveInsight, the Open-Angle Glaucoma market in 7MM is expected to witness a major change in the study period 2019-2032.

• The leading Open-Angle Glaucoma Companies include Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical/Ube Industries, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp., Novartis/Alcon Research, Novartis company, Allergan, Sun Pharma Advanced Research Company Limited (SPARC), Laboratorios Sophia S.A de C.V., Perrigo Company, Chong Kun Dang Pharmaceutical, Nicox Ophthalmics, Sylentis, Envisia Therapeutics, Ocuphire Pharma, Peregrine Ophthalmic, and others

• Promising Open-Angle Glaucoma Pipeline Therapies include PDP-716, TC-002, Omidenepagisopropyl, DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others

To Know in detail about the Open-Angle Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Open-Angle Glaucoma Market Insights- https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Open-Angle Glaucoma Overview
Glaucoma is an eye disease that gradually steals vision. Open-Angle Glaucoma is the most common type of glaucoma. Open-Angle Glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. Glaucoma affects 70 million people worldwide and is the second leading cause of blindness. The underlying pathology of Open-Angle Glaucoma lies in the apoptosis of retinal ganglion cells. Open-Angle Glaucoma can be clinically evaluated using a variety of diagnostic tools including optic disc changes, visual field changes, and elevated intraocular pressure. The goal of treatment of Open-Angle Glaucoma is to prevent the progression of optic nerve head changes and also the prevention of deterioration of visual field.

Open-Angle Glaucoma Epidemiology Segmentation in the 7MM
• Total Open-Angle Glaucoma Diagnosed Prevalence
• Open-Angle Glaucoma Gender-specific Diagnosed Prevalence
• Open-Angle Glaucoma Age-specific Diagnosed Prevalence
• Open-Angle Glaucoma Type-specific Diagnosed Prevalent Population
• Open-Angle Glaucoma Type-specific Diagnosed Prevalence
• Open-Angle Glaucoma Type-specific Diagnosed Prevalence of Secondary

Download the report to understand which factors are driving Open-Angle Glaucoma epidemiology trends @ Open-Angle Glaucoma Epidemiological Insights- https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Open-Angle Glaucoma Emerging Drugs

• QLS-101: Qlaris Bio
QLS-101 is a novel topical ocular therapy that lowers intraocular pressure. QLS-101 modulates KATP channel by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP). Qlaris Bio has initiated clinical studies with QLS-101 in patients with Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma, and Sturge-Weber syndrome.

• Razuprotafib: Aerpio Pharmaceuticals
Razuprotafib is a novel small molecule Tie2 activator that enhances endothelial function and stabilizes blood vessels, including pulmonary and renal vasculature. Razuprotafib (AKB-9778) topical drops is currently under Phase II clinical evaluation for treatment of primary open angle glaucoma (POAG).

Open-Angle Glaucoma Market Landscape
Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. To improve the treatment scenario, globally, several key companies are actively working to develop new therapies for the treatment of Open-Angle Glaucoma. Several of the therapies are in the advance of clinical development, anticipated to hit the market in the near future.

Find out more about the Open-Angle Glaucoma Pipeline Segmentation, Therapeutics Assessment, and Open-Angle Glaucoma Emerging Drugs @ Open-Angle Glaucoma Treatment Landscape- https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Open-Angle Glaucoma Market Report

• Coverage- 7MM

• Open-Angle Glaucoma Companies- Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical/Ube Industries, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp., Novartis/Alcon Research, Novartis company, Allergan, Sun Pharma Advanced Research Company Limited (SPARC), Laboratorios Sophia S.A de C.V., Perrigo Company, Chong Kun Dang Pharmaceutical, Nicox Ophthalmics, Sylentis, Envisia Therapeutics, Ocuphire Pharma, Peregrine Ophthalmic, and others

• Open-Angle Glaucoma Pipeline Therapies- PDP-716, TC-002, Omidenepagisopropyl, DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others.

• Open-Angle Glaucoma Market Dynamics: Open-Angle Glaucoma Market Drivers and Barriers

• Open-Angle Glaucoma Market Access and Reimbursement, Unmet Needs

Dive deep into rich insights for drugs for Open-Angle Glaucoma Pipeline Companies and Therapies, click here @ Open-Angle Glaucoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Open-Angle Glaucoma
3. Competitive Intelligence Analysis for Open-Angle Glaucoma
4. Open-Angle Glaucoma: Market Overview at a Glance
5. Open-Angle Glaucoma: Disease Background and Overview
6. Patient Journey
7. Open-Angle Glaucoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Open-Angle Glaucoma Unmet Needs
10. Key Endpoints of Open-Angle Glaucoma Treatment
11. Open-Angle Glaucoma Marketed Products
12. Open-Angle Glaucoma Emerging Therapies
13. Open-Angle Glaucoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Open-Angle Glaucoma Market Outlook
16. Access and Reimbursement Overview of Open-Angle Glaucoma
17. KOL Views
18. Open-Angle Glaucoma Market Drivers
19. Open-Angle Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Open-Angle Glaucoma Mergers and acquisitions, Open-Angle Glaucoma Licensing Activities @ Open-Angle Glaucoma Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.